

February, 4<sup>th</sup> / 2010

## Bicoll News – 2010

Welcome to the 2010 edition of **Bicoll News**. For those familiar with Bicoll's yearly newsletter, you know that every new year starts with a snapshot of topics concerning our last year that aims to provide an overview of our services and capabilities. As always we like to thank you, our loyal customers, partners and friends for your ongoing support and trust in Bicoll's business.

2009 has been a busy and challenging year for most in the sector of pharmaceutical and biotech research. As challenge is a strong impulse for development, Bicoll has kept on expanding its innovation-driven drug discovery and medicinal chemistry R&D and service platform. 2009 has also been a year of successful partnering with many US and European life science partners for Bicoll. And not to forget our changing visual appearance reflecting steady growth. The new company website tells you more about how we might be able to help you get ahead and stay ahead in drug discovery and medicinal chemistry projects.

We are looking forward to hearing from you and meeting you in 2010.

Yours sincerely,



Dr. Kai Lamottke  
Managing Director



Dr. Christian Haug  
Managing Director

### TOPICS

- Successful preliminary results in a joint research project in drug discovery from natural products with our partner Genfit SA
- Modernization of our laboratory facilities with focus on medicinal chemistry
- New Advisory Board member for Bicoll – Dr. Michael Bogenstaetter joins the team of experts
- What to expect from Bicoll in 2010 – projected development of our analytical department and enlargement of medicinal chemistry team; extension of drug discovery cooperations

## Successful preliminary results in a joint research project in drug discovery from natural products with our partner Genfit SA

**Together** with our collaboration partner Genfit SA (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, Bicoll announced successful preliminary results of a joint research project in September 2009. The project "OLNORME: Occurrence of novel Ligands for a Nuclear Orphan Receptor in plant Metabolites" has identified first active and confirmed hits for a class of new drugs and elucidated their structures.

OLNORME was originally launched in 2007 and is currently an important drug research project at our partner GENFIT. The project is based on the screening of Profiles™ from Bicoll's highly diversified library of plant metabolites and aims at identifying promising compounds, which will serve as hits for a class of new drugs. These drug candidates will hold great potential for therapeutic use - as a first priority in inflammation related diseases including cardiometabolic and neurodegenerative disorders. More than 12,000 Profiles™ from plants (equals around 100.000 different small molecules) have been submitted by Bicoll to Genfit's robust screening system, yet.

You may want to read more at

[http://www.bicoll-group.com/downloads-pr/090901\\_Bicoll\\_Genfit\\_Olnorme\\_ENGLISH.pdf](http://www.bicoll-group.com/downloads-pr/090901_Bicoll_Genfit_Olnorme_ENGLISH.pdf)

## Modernization of our laboratory facilities with focus on medicinal chemistry

**The** modernization of our laboratory facilities for medicinal chemistry within Zhangjiang Hi-Tech Park, Shanghai, was completed in October 2009. With the new facilities we are now able to meet an increasing demand for medicinal chemistry research and consulting services.

At our central laboratory facility in Shanghai, we provide pre-clinical support in the area of drug discovery from natural products and medicinal chemistry. "We recognize a growing number of requests for sophisticated synthesis technologies," knows Dr. Martin Braun, Vice President of Medicinal Chemistry at Bicoll. "This modernization will help our experienced chemists in front-line medicinal chemistry to continue providing rapid synthesis of lead compound series for any therapeutic area. We are prepared for any size of projects: From small quantities to multi-gram scale projects."

## **New Advisory Board member for Bicoll – Dr. Michael Bogenstaetter joins the team of experts**

Dr. Michael Bogenstaetter joined Bicoll's long-term advisors Dr. Hardy Debuch, Prof. Dr. Thorsten Bach, Prof. Dr. Peter Vollhardt and Sina Afra in June 2009. We appreciate working with Michael as he has over 15 years of experience in biopharmaceutical research and life science management & strategy. He is one of the few experts with a deep knowledge spanning from pharmaceutical research (academia, J&J) to commercial & strategic objectives (Novartis, The Boston Consulting Group). Currently, Michael is VP of Strategy & Corporate Development at MDS Inc., driving strategic acquisitions and divestitures.

"Leveraging biodiversity to discover novel medicines has solid precedent and proven commercial success; Bicoll uniquely positioned itself to bring this paradigm to a renaissance through its quantum leap approach and technology advancement. It is a real privilege to continue contributing to this endeavor", Michael commented his appointment.

## **What to expect from Bicoll in 2010 – projected development of our analytical department and enlargement of medicinal chemistry team; extension of drug discovery co-operations**

In 2010 you can count on us focusing on our core competencies to meet your needs: Drug discovery from natural products and medicinal chemistry. Hence we will continue to extend our analytical department serving both business units. In addition the increasing demand for sophisticated synthesis technologies is driving us to re-increase our highly educated team of medicinal chemistry in 2010 as well.

We will stay committed to discover novel, active small molecules for the development of the next generation of innovative drugs, agrochemicals, nutraceuticals and cosmeceuticals in strong partnerships. Therefore we will continue in entering in numerous, valuable co-operations with academia and renown and rising companies from the pharmaceutical and biotechnology sectors.

We hope to stay in contact with you as much as possible, so don't miss to call, send e-mails or visit our research facilities in Shanghai/ China and the headquarters in Munich/ Germany. We are looking forward to hearing from you.